ReviewNature reviews. Cardiology2022
A fresh look at coronary microembolization.
Review in Nature reviews. Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 2 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Diagnostic and prognostic value of angiography-derived index of microvascular resistance: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Microcirculation function assessment in acute myocardial infarction: A systematic review of microcirculatory resistance indices.Frontiers in cardiovascular medicine · 2022Pooled it
- Prognostic Value of Angiographic Microcirculatory Resistance After Coronary Intervention: Insights From the FAVOR III China Trial.Journal of the American Heart Association · 2026Trial
- Dapagliflozin prevents vascular ischemia-reperfusion injury in healthy young males: a randomized, placebo-controlled, double-blinded trial.Scientific reports · 2025Trial
- Chronic remote ischemic conditioning treatment in patients with chronic stable angina (EARLY-MYO-CSA): a randomized, controlled proof-of-concept trial.BMC medicine · 2023Trial
- Role of ST-Segment Resolution Alone and in Combination With TIMI Flow After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction.Journal of the American Heart Association · 2023Trial
- Prolonged infusion of bivalirudin after elective percutaneous coronary intervention protects against procedural myocardial injury (a COBER study)-a randomized trial.Scientific reports · 2023Trial
- Historical account of reperfusion therapy and the development of cardioprotection beyond reperfusion.Basic research in cardiology · 2026Review
- Molecular mechanisms of coronary microembolization-induced MINOCA.Basic research in cardiology · 2026Review
- Reperfusion injury from a haemodynamic standpoint and role of pressure-controlled reperfusion in avoiding reperfusion injury.European heart journal open · 2026Review
- Finerenone attenuates myocardial injury and enhances vascular repair via regulation of autophagy, apoptosis, and angiogenesis.Scientific reports · 2026Article
- Comparing anti-platelet and anti-thrombin therapies in the ischaemia-reperfusion injured coronary microcirculation of healthy and diabetic mice.Basic research in cardiology · 2026Article
- A single-center observational study on the impact of intravascular ultrasound-detected attenuated plaque on coronary microvascular dysfunction following percutaneous coronary intervention.The international journal of cardiovascular imaging · 2026Observational
- Myocardial ischemia: no supply/demand mismatch but reduced blood flow per beat.Basic research in cardiology · 2026Review
- Induction of ischaemic cardiomyopathy in mice without off-target effects.Experimental physiology · 2026Article
- Establishment of a mouse model for ischaemic heart failure induced by coronary microembolization via left ventricular oil injection.Experimental physiology · 2026Article
- Semaglutide ameliorates coronary microembolization-induced injury by suppressing apoptosis and inflammation via the HMGB1/RAGE/NF-κB p65 pathway.Journal of geriatric cardiology : JGC · 2026Article
- Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Vessel.Cardiology research · 2026Article
- Platelet-derived growth factor-BB is a novel inflammatory biomarker of no-reflow in STEMI patients treated with primary PCI.Journal of thrombosis and thrombolysis · 2026Observational
- Molecular and Cellular Mechanisms of Myocardial Ischemia and Reperfusion Injury: A Narrative Review.Cells · 2026Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanical stress from haemodynamic perturbations or interventional manipulation of epicardial coronary atherosclerotic plaques with inflammatory destabilization can release particulate debris, thrombotic material and soluble substances into the coronary circulation. The physical material obstructs the coronary microcirculation, whereas the soluble substances induce endothelial dysfunction and facilitate vasoconstriction. Coronary microvascular obstruction and dysfunction result in patchy microinfarcts accompanied by an inflammatory reaction, both of which contribute to progressive myocardial contractile dysfunction. In clinical studies, the benefit of protection devices to retrieve atherothrombotic debris during percutaneous coronary interventions has been modest, and the treatment of microembolization has mostly relied on antiplatelet and vasodilator agents. The past 25 years have witnessed a relative proportional increase in non-ST-segment elevation myocardial infarction in the presentation of acute coronary syndromes. An associated increase in the incidence of plaque erosion rather than rupture has also been recognized as a key mechanism in the past decade. We propose that coronary microembolization is a decisive link between plaque erosion at the culprit lesion and the manifestation of non-ST-segment elevation myocardial infarction. In this Review, we characterize the features and mechanisms of coronary microembolization and discuss the clinical trials of drugs and devices for prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.